This study was conducted to investigate the diagnostic performance characteristics of prostate specific antigen (PSA) by comparing serum PSA value with histological findings in patients suspected of having prostate cancer in Aminu Kano Teaching Hospital. Nigeria. Clinical and Laboratory records were examined and collated for serum PSA values, together with histological findings of biopsy specimen, clinical diagnosis, age of patients, and mode of presentation. The serum PSA values were determined by ELECSYS 1010 autoanalysers Roche, Germany based on electrochemiluminescence immunoassay technique. The results show that serum PSA values increase with age in the assymptomatic non-cancer patients who came for medical check up but were within normal limit. In prostatic disease conditions PSA values were raised in benign prostatic hyperptasia 35.957+ 4.0315ng/ml, in undifferentiated carcinoma 56.22 + 4.295 ng/ml and adenocarcinoma >100 ng/ml as compared to the normal range (0-4 ng/ml). These cases were confirmed by histological diagnosis. It is concluded that PSA evaluations is a sensitive marker for prostate cancer but because of various other conditions that affect serum PSA concentration, other methods of investigations such as Digital Rectal examination, Trans Urethral Ultra-Sonography and histological examination should be combined to confirm diagnosis. Prognosis of patients will be better if early diagnosis is made.
INTRODUCTION
The advent of prostate specific antigen (PSA) has made prostate cancer the most common malignancy in men above 50 years and the third most common cause of cancer death in the United State of American (1) (2) (3) . The prognosis of patients with prostate cancer is dependent on the stage and grade of the tumour at the time of diagnosis. Many patients who are diagnosed by PSA assay have no palpable prostatic nodules and cancer documented by means of ultrasound guided or blind biopsies (4) . Prostate cancer causes significant morbidity and mortality in African men (5) . There is a need for health education about the early detection of the disease. Clinically the diagnosis of prostate cancer is strongly suggested by a hard irregular prostate or by an elevated PSA, but diagnosis is confirmed by histological examinations of biopsy, transurethral prostate resection chip specimen or by Author for Correspondence:
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aspiration cytology (6) . Advocates of prostate cancer screening argue that PSA measurement would help to select an at risk group while transurethral ultrasonography (TRUS) and biopsy would identify clinically occult early tumours in this group (6) .
This article evaluates the performance of serum PSA measurement in patients suspected of having prostate cancer and comparing with histological examination of prostate biopsy specimens.
PATIENTS AND METHODS
A retrospective study of all patients who were referred to the Chemical Pathology department of Aminu Kano Teaching Hospital, Kano, Nigeria for serum PSA was included in the study. The histopathology Laboratory records and medical records were searched for the patient who's serum PSA Level was determined between December 2000 and August 2002. The hospital records were searched for diagnosis, age of the patients on presentation and mode of presentation. The histopathology records were searched for microscopic diagnosis which was compared with PSA levels to determine the sensitivity and specificity of PSA assay. The PSA assay was carried out using ELECSYS 1010 ANALYSER, Roche, Germany, based on electrochemiluminescence immunoassay technique. Statistical analysis was done by ANOVA diskette using Compaq micro computer of the hospital.
RESULTS
A total of one hundred and forty five (145) patients were referred to the department for PSA determination. (Table 1) The age ranged from 43 years to 98 years with the mean age of 67.9 years. The PSA values obtained were stratified to different PSA groups (0-4ng/ml; 4.1-20ng/ml;20.1-99ng/ml;and 99.1->100ng/ ml respectively)and age groups (table1). Forty of them came for routine PSA check, thirty seven patients were younger than 60 years of age and twelve patients were older than 61 years. The hospital records of fifty of the patients who were admitted and treated in the hospital were traced ( Table 2 ). The age of the patients range from 43 years to 98 years. The mode of presentation include urine frequency, terminal dribbling, suprapubic pain and urine retention (24), paraplegia and in ability to walk (20) lower back pain and abdominal pain (4) and haematuria (2) . The number of patients with moderately and well differentiated prostatic adenocarcinoma were 27, two of the patients were aged 48-50 years, four were 51-60 years; ten were 61-70 years eight were 71-80 years and three were 81-98 years. Those with poorly differentiated carcinoma were 10 and three of them were aged 46-50 years, six were 71-80 years and one was 81-96 years old. While those with benign prostatic hyperplasia were 13. Twelve of them were aged 61-70 years while 2 were aged 51-60 years (table 3) .
DISCUSSION
Detection of prostate cancer by screening for elevated level of PSA is increasingly popular in this centre. The most common prostate cancer screening tools are Digital rectal examination (DRE), Transrectal ultrasonography (TRUS) and PSA assay. PSA is the most clinically useful tumour marker for diagnosis of prostate cancer. Although specific for prostatic tissue, it is not prostate cancer specific (7) . It has been reported that Ig of benign hyperplastic tissue (benign prostatic hyperplasia (BPH) gives rise to 0.2-0.3ng/ml of PSA in the serum (1, 8-10 ). Similarly serum PSA concentration directly correlated with patient's age and prostatic volume, in other word, as men grew older their prostate glands enlarge and PSA concentration increases. Table 1 in this study shows that serum PSA values increased with age in the 0-4ng/ml column. Within the age range of 40-49 the PSA value was 1.133 + 0.29ng/ ml; 50-59 years (1.238 + 0.233ng/ml); 60-69 years (1.607 • 0.517ng/ml) and 70-79 years 1.808 + 0.408ng/ ml) (Figure 1 ). Apart from prostatic volume, other factors contributing to increase in PSA as men age include episodes of subclinical or clinical prostatitis, intermittent bouts of prostatic ischemia, infarction and the presence of prostate cancer that cannot be detected by currently available methods. Furthermore, as men grew older, their prostate glands may become more "leaky'. The normal physiological barriers that keep PSA in the prostate duct system may become more permeable and allow serum PSA to enter the general circulation via the capillaries and lymphatics(11 ). If all the records were found it would have been interesting to know the causes of the rise in the 4.1-20-ng/ml column (Table 1) . However, it might be unconnected with the factors enumerated above. Five patients were discharged on financial plea or against medical advice before further investigations were carded out. From table 3, thirteen of the patients had BPH and their PSA mean value was 35.957 + 4.035ng/ml. This was confirmed by histological microscopy. Ten had undifferentiated carcinoma and mean serum PSA value of 56.22 + 4.295nglml while twenty seven had adenocarcinoma with mean PSA value >100nglml. These also were confirmed by histological microscopy.
The reference range of serum PSA use in this centre is 0-4ng/ml. A PSA value above 4ng/ml signals the need for further investigations. It is important to state that in men with normal size prostate, a PSA value above 2ng/ml may raise concerns for prostate cancer. The percent free PSA will be helpful for men with PSA values less than 10ng/ml to enable definitive diagnosis to be made (12). There may be indication for prostate cancer when percent free PSA reading of 25% in men with a PSA value of 4.1-10ng/ml is recorded or 15% with PSA of 2.5-4ng/ml. There was one patient whose
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PSA was within normal limit but cancer detected at autopsy. Some men's prostate (cancer) tissue does not secrete much PSA even in the presen of prostate cancer (12).
PSA is also very important in treatment monitoring. The steepness of the rate of fall in PSA down to undetectable levels following adequate treatment provides information on the success of therapy (13).
In summary, the finding of this investigation indicates that the serum PSA is effective in the diagnosis of prostate cancer. BPH can lead to considerable rise in PSA levels. Nevertheless, a mild to moderate rise in serum PSA level alone (without having any other concurrent diagnostic procedure) may prove inadequate in the diagnosis and confirmation of prostate cancer, and this may even lead to a false and misleading conclusion by a clinician.
To obtain good performance from PSA evaluation, blood samples for PSA should be taken first before any physical manipulation of the prostate gland. When PSA is combined with other methods of diagnosis of this all important cancer, early diagnosis will be made possible. And prognosis of patients will be better. 
